The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: Long-term follow-up

Pulmonary Circulation

Volumn 4, Issue 4, 2014, Pages 619-629

  Vitali, Sally H ^a   Hansmann, Georg ^a,b   Rose, Chase ^a   Fernandez Gonzalez, Angeles ^a   Scheid, Annette ^a   Mitsialis, S Alex ^a   Kourembanas, Stella ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Animal model; Hypoxia; Pulmonary hypertension; Right ventricle; Sugen 5416

Indexed keywords

EID: 85026336399     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/678508     Document Type: Article

References (38)

1. Gomez-Arroyo J, Saleem SJ, Mizuno S, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 2012;302:L977-L991.
2. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438.
3. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, et al. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ 2012;2:434-442.
4. Abe K, Toba M, Alzoubi A, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747-2754.
5. Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100: 923-929.
6. Ciuclan L, Bonneau O, Hussey M, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182.
7. Hansmann G, Fernandez-Gonzalez A, Aslam M, et al. Mes-enchymal stem cell-mediated reversal ofbronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ 2012;2:170-181.
8. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardio-graphic-angiographic correlations in the presence ofabsence ofasynergy. Am J Cardiol 1976;37:7-11.
9. Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel MC, Tan HL. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr 2006;19:1272-1279.
10. Hansmann G, Wagner RA, Schellong S, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-y activation. Circulation 2007;115:1275-1284.
11. Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the World Health Organisation's categorisation of human PH. Int J Clin Pract Suppl 2011;Aug:15-34.
12. Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARy/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008;118:1846-1857.
13. Jonigk D, Golpon H, Bockmeyer CL, et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011;179:167-179.
14. Tabima DM, Hacker TA, Chesler NC. Measuring right ventricular function in the normal and hypertensive mouse hearts using admittance-derived pressure-volume loops. Am J Physiol Heart Circ Physiol 2010;299:H2069-H2075.
15. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-1041.
16. Koestenberger M, Nagel B, Avian A, et al. Systolic right ventricular function in children and young adults with pulmonary artery hypertension secondary to congenital heart disease and tetralogy of Fallot: tricuspid annular plane systolic excursion (TAPSE) and magnetic resonance imaging data. Congenit Heart Dis 2012;7:250-258.
17. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models ofpulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
18. Erzurum S, Rounds SI, Stevens T, et al. Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med 2010;182:1554-1562.
19. Rabinovitch M, Chesler N, Molthen RC. Point:counterpoint: chronic hypoxia-induced pulmonary hypertension does/does not lead to loss of pulmonary vasculature. J Appl Physiol 2007;103:1449-1451.
20. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-1495.
21. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-450.
22. Levi M, Moons L, Bouche A, Shapiro SD, Collen D, Carme-liet P. Deficiency of urokinase-type plasminogen activatormediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 2001;103:2014-2020.
23. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-244.
24. Yared K, Noseworthy P, Weyman AE, McCabe E, Picard MH, Baggish AL. Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. J Am Soc Echocardiogr 2011;24:687-692.
25. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 2002;283:H364-H371.
26. Bonnet P, Bonnet S, Boissiere J, et al. Chronic hypoxia induces nonreversible right ventricle dysfunction and dysplasia in rats. Am J Physiol Heart Circ Physiol 2004;287:H1023-H1028.
27. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010;299:L401-L412.
28. Koskenvuo JW, Mirsky R, Zhang Y, et al. A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging 2010;26:509-518.
29. Kitabatake A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983;68:302-309.
30. Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Dopp-ler echocardiography. Am J Cardiol 1987;59:662-668.
31. Isobe M, Yazaki Y, Takaku F, et al. Prediction of pulmonary arterial pressure in adults by pulsed Doppler echocar-diography. Am J Cardiol 1986;57:316-321.
32. Thibault HB, Kurtz B, Raher MJ, et al. Noninvasive assessment ofmurine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. Circ Car-diovasc Imaging 2010;3:157-163.
33. Okamoto M, Miyatake K, Kinoshita N, Sakakibara H, Ni-mura Y. Analysis of blood flow in pulmonary hypertension with the pulsed Doppler flowmeter combined with cross sectional echocardiography. Br Heart J 1984;51:407-415.
34. Bogaard HJ, Natarajan R, Henderson SC, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951-1960.
35. Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-660.
36. Mertens LL, Friedberg MK. Imaging the right ventricle— current state of the art. Nat Rev Cardiol 2010;7:551-563.
37. Toldo S, Bogaard HJ, Van T, et al. Right ventricular dysfunction following acute myocardial infarction in the absence of pulmonary hypertension in the mouse. PLoS ONE 2011;6:e18102.
38. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 2004;164:253-262.